Follow
Kyle M. Garland
Kyle M. Garland
Eterna Therapeutics, Inc.
Verified email at eternatx.com - Homepage
Title
Cited by
Cited by
Year
Chemical and biomolecular strategies for STING pathway activation in cancer immunotherapy
KM Garland, TL Sheehy, JT Wilson
Chemical reviews 122 (6), 5977-6039, 2022
1162022
Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma
L Wang-Bishop, M Wehbe, D Shae, J James, BC Hacker, K Garland, ...
Journal for immunotherapy of cancer 8 (1), 2020
1152020
STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy
L Wang-Bishop, BR Kimmel, VM Ngwa, MZ Madden, JJ Baljon, ...
Science immunology 8 (83), eadd1153, 2023
192023
Pharmacological activation of cGAS for cancer immunotherapy
KM Garland, JC Rosch, CS Carson, L Wang-Bishop, A Hanna, S Sevimli, ...
Frontiers in Immunology 12, 753472, 2021
182021
A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA
CS Carson, KW Becker, KM Garland, HM Pagendarm, PT Stone, K Arora, ...
Journal of Controlled Release 345, 354-370, 2022
172022
Microparticle depots for controlled and sustained release of endosomolytic nanoparticles
KM Garland, S Sevimli, KV Kilchrist, CL Duvall, RS Cook, JT Wilson
Cellular and Molecular Bioengineering 12, 429-442, 2019
132019
Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy
L Wang-Bishop, M Wehbe, LE Pastora, J Yang, BR Kimmel, KM Garland, ...
ACS nano, 2024
2024
Nanoparticle Delivery of Immunostimulatory Alu RNA for Cancer Immunotherapy
KM Garland, AJ Kwiatkowski, JT Tossberg, PS Crooke III, TM Aune, ...
Cancer Research Communications 3 (9), 1800-1809, 2023
2023
A Nanoparticle RIG-I Agonist for Cancer Immunotherapy
L Wang-Bishop, M Wehbe, LE Pastora, J Yang, KM Garland, KW Becker, ...
bioRxiv, 2023.04. 25.537919, 2023
2023
Engineering Innate Immune Activators for Intratumoral Immunotherapy
KM Garland
2021
The system can't perform the operation now. Try again later.
Articles 1–10